COMP <GO>
EW vs MRK // OPERATING MARGIN
Edwards Lifesciences Corporation (NYSE) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: EW 6
— MRK 9
▲ OPERATING MARGIN LEADER: MRK
LAST: $92.01 (-2.57%) • MKT CAP: $54.44B
operating-margins
20.80%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
operating-margins
34.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EW VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EW | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 78.00% | 74.80% | +3.20 | EW | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 12.50% | 20.70% | -8.20 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 35.1x | 15.3x | +19.80 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 2.45% | 3.42% | -0.97 | MRK | /fcf-yield <GO> |
| Operating Margin ACTIVE | 20.80% | 34.30% | -13.50 | MRK | /operating-margins <GO> |
| Net Profit Margin | 17.70% | 28.10% | -10.40 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 11.50% | 1.30% | +10.20 | EW | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 12.36 | 5.19 | +7.17 | EW | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | EW | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.60% | +0.60 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.9 | 56.9 | +3.01 | EW | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 0.92 | +0.16 | EW | /macro-sensitivity <GO> |
| Forward P/E Multiple | 47.2x | 18.4x | +28.80 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $54.44B | $361.02B | -$306.59B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EW REV | MRK REV | EW GROSS % | MRK GROSS % | EW FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $6.07B | $65.01B | 78.0% | 74.8% | $1.33B | $12.36B |
| FY 2024 | $5.44B | $64.17B | 79.5% | 76.3% | $289.9M | $18.10B |
| FY 2023 | $5.01B | $60.12B | 44.0% | 44.0% | $670.4M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EW // BETA 1.08
MRK // BETA 0.92